| Literature DB >> 31007536 |
Ruwandi Kariyawasam1, Avinash N Mukkala1, Rachel Lau2, Braulio M Valencia3,4, Alejandro Llanos-Cuentas3,5, Andrea K Boggild1,2,6,7.
Abstract
BACKGROUND: Leishmania RNA virus-1 (LRV1) is a double-stranded RNA virus identified in 20-25% of Viannia-species endemic to Latin America, and is believed to accelerate cutaneous to mucosal leishmaniasis over time. Our objective was to quantify known virulence factor (VF) RNA transcript expression according to LRV1 status, causative species, and isolate source.Entities:
Keywords: American tegumentary leishmaniasis; Leishmania RNA Virus-1 (LRV1); Leishmania Viannia braziliensis; Virulence factor
Year: 2019 PMID: 31007536 PMCID: PMC6458769 DOI: 10.1186/s41182-019-0153-x
Source DB: PubMed Journal: Trop Med Health ISSN: 1348-8945
Classification of Leishmania spp. strains used in experiments
| Source of isolate | Country of acquisition | LRV1 status | Relative LRV1 copy number | Age | Sex | Clinical phenotype | |
|---|---|---|---|---|---|---|---|
| ATCC (MHOM/BR/75/M2903) | Brazil | LRV1− | NA | Unk | Unk | Unk | |
| Clinical | Peru | LRV1+ | 0.1 | 22 | Male | Severe | |
| ATCC (MHOM/BR/75/M4147) | Brazil | LRV1+ | Reference [ | Unk | Unk | Unk | |
| ATCC (MHOM/PA/71/LS94) | Unknown | LRV1− | NA | Unk | Unk | Unk | |
| Clinical | Costa Rica | LRV1− | NA | 80 | Male | Severe | |
| Clinical | Costa Rica | LRV1− | NA | 17 | Male | Non-severe | |
| Clinical | Ecuador | LRV1+ | 2.17 × 10−4 | 9 | Male | Severe | |
| Clinical | Costa Rica | LRV1+ | 1.02 × 10−4 | 71 | Male | Severe |
Primer and probe sequences used to detect virulence factor RNA transcripts by real-time PCR
| Target | Sequence |
|---|---|
| 18S | |
| Forward | 5′-AAGTGCTTTCCCATCGCAACT-3′ |
| Reverse | 5′-GACGCACTAAACCCCTCCAA-3′ |
| Probe | FAM-CGGTTCGGTGTGTGGCGCC-NFQ |
| GP63 | |
| Forward | 5′-GGCTTCTACCAGGCGGACTT-3′ |
| Reverse | 5′-TGATGYbYbBTBCRaCCATGCACTT-3′ |
| Probe | FAM-AGGCCGAGGTGATG-MBG |
| CPB | |
| Forward | 5′-GCTCGTCGGGTACAACAAGAC-3′ |
| Reverse | 5′-AGTCCTCACCCCACGAGTTCT-3′ |
| Probe | FAM-TTCCGTACTGGGTGATC-BHQ1 |
| MPI | |
| Forward | 5′-GCTGCGAGGCCGGATAA-3′ |
| Reverse | 5′-GGAGTCAAGGCGCARaATGAG-3′ |
| Probe | FAM-TACAAGGACCCGAACCACARaGCCTGA-BHQ1 |
| HSP23 | |
| Forward | 5′-GARaCGScTGCTTCGAGCTT-3′ |
| Reverse | 5′-GAAGScTGGCCTTGATTTTGC-3′ |
| Probe | FAM-CTGTTCGAGCTTC-BNFQ |
| HSP70 | |
| Forward | 5′-GTGGAWdATCATCGCGAACGA-3′ |
| Reverse | 5′-GAGTCCGTGAACGCAACGTA-3′ |
| Probe | FAM-AGGGYbAACCGCACGACACCGT-BHQ1 |
| HSP90 | |
| Forward | 5′-CAAGAAGCGCAACAACATCAA-3′ |
| Reverse | 5′-TCGCAGTTGTCCATGATGAAC-3′ |
| Probe | FAM-TGTACGTGCGCCGCG-BHQ1 |
| HSP100 | |
| Forward | 5′-CCGACTTCCARaGACGACAAC-3′a |
| Reverse | 5′-GCCTGCTTGCAGAGATCRaA-3′ |
| Probe | FAM-ACGAGTCACTGAACAAG-BHQ1 |
aR = A,G
bY = C,T
cS = C,G
dW = A,T
Fig. 1Log transformed virulence factor RNA transcript expression in baseline cultures and supernatants post-macrophage infectivity at 24 and 48 h compared by Kruskal-Wallis or Mann-Whitney for the following targets: pooled expression (a), cpb (b), gp63 (c), mpi (d), hsp70 (e), hsp90 (f), and hsp100 (g)